This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...

市场可能过于关注新药的波动性销售。礼来公司仍将从减肥药物销售的巨大市场增长中受益。对于在此投资的投资者来说，该股票提供了通过将损失限制在当前水平的约5%以内来保护下行风险的机会，如果年线支撑位无法守住的话。

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

People claim the viral "natural Mounjaro" drink — honey, lemon, water, and ginger — makes you lose weight. Here's what an ...

周三，尽管制药公司礼来 (NYSE:LLY)第四季度收入未达市场预期，富国银行仍重申了其对礼来股票的"增持"评级和1,000.00美元的目标价。礼来报告的收入为135亿美元，低于约140亿美元的一致预期。

A so-called "natural Mounjaro" drink has gone viral online thanks to claims it can lead to significant weight loss. Here's ...

印第安纳波利斯 - 目前市值超过7,180亿美元，交易价格高于其 InvestingPro 公允价值的礼来公司（NYSE:LLY）今日宣布，预计2024年全年收入将达到约450亿美元，较上年显著增长32%。这家制药巨头保持着令人印象深刻的80.9%的毛利率，同时预测2025年收入将在580亿美元至610亿美元之间，显示出持续的增长势头。

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...

Kenvue isn't growing as quickly as Eli Lilly or Zoetis, but it offers investors a strong starting point for dividend income.

Research reveals groundbreaking results about Mounjaro and Ozempic in weight loss treatment. Here's what you need to know ...